An antibacterial agent and oral care solution for inhibiting volatile sulfur compounds.

Abstract

This invention discloses a formulation and oral care solution for inhibiting bacteria and volatile sulfur compounds. The formulation comprises concentrated Camellia chrysanthemum extract and coconut oil, wherein the mass ratio of concentrated Camellia chrysanthemum extract to coconut oil is (24-72):(25-75). Through the synergistic effect of concentrated Camellia chrysanthemum extract and coconut oil, the formulation utilizes the synergistic effect of Camellia chrysanthemum extract against Staphylococcus albus, Pseudomonas aeruginosa, Streptococcus beta-2, and Corynebacterium diphtheriae. Combined with the antibacterial and antioxidant properties of coconut oil, a stronger antibacterial effect is achieved, and volatile sulfur compounds can be effectively inhibited, thus preventing and eliminating halitosis.

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of oral care liquids, in particular to a preparation for inhibiting bacteria and volatile sulfur compounds and an oral care liquid. BACKGROUND

[0002] It is well known that in most cases, the source of oral malodor is the volatile sulfur compounds (VSCs) produced by bacteria in the oral cavity, mainly hydrogen sulfide (H2S) and methyl mercaptan (MM). Bacteria produce methionine and cysteine, which contain sulfur functional groups, through protein hydrolysis and anaerobic metabolism, playing a role as precursors of volatile sulfur compounds (VSCs). The most important substrate of H2S is cysteine, and methionine is the main substrate for the formation of MM. These substances have an extremely unpleasant odor even at very low concentrations. VSCs can also penetrate epithelial cells and have pathogenic potential by affecting their metabolism by damaging underlying tissue cells. The VSCs produced by bacteria in the periodontal pocket may be an important factor in the occurrence of periodontal disease, among which methyl mercaptan seems to have a higher pathogenic potential than hydrogen sulfide, and the odor is also more unpleasant. Oral malodor has become a problem that the public urgently needs to solve due to personal and social discomfort, and the market for products to prevent oral malodor is growing continuously.

[0003] Among various prevention and treatment compositions, combinations of chlorine-containing compounds and metal salts are used as neutralizing agents for VSCs. Commonly used zinc salts (chloride, sulfate and citrate) can reduce the production of VSCs in the oral cavity and also have certain antibacterial activity, which can inhibit the formation of dental plaque. In combination with chlorine-containing antibacterial compounds, it can cause the production of low-solubility salts (such as chlorhexidine) to cause tooth stains, and other cationic antibacterial agents such as cetylpyridinium chloride or benzalkonium chloride have poor clinical effects. In summary, oral products with these ingredients have low toxicity and irritation, and long-term use can cause oral inflammation, ulcers and peeling. In view of the above problems, it is an increasingly growing demand to design a mild and effective antibacterial care liquid that inhibits volatile sulfur compounds and prevents and treats oral diseases and oral malodor.

[0004] In the prior art, CN108653081A discloses a compound golden camellia tea mouthwash, which is composed of golden camellia leaves, tumorous wind, glycerol, edible alcohol, menthol, potassium sorbate, sodium saccharin, etc., to improve the effect of the mouthwash on resisting pathogenic bacteria of dental caries, Streptococcus mutans and Lactobacillus acidophilus. CN110522673 discloses an oral care composition, which comprises: a) baking soda, b) an anionic surfactant, c) a cationic or amphoteric surfactant, d) coconut oil, and e) an orally acceptable carrier, but the purpose of adding coconut oil is to improve the significant reduction in the amount and density of foam caused by the addition of baking soda. In summary, there is no literature that uses golden camellia tea and coconut oil to design a mild, effective antibacterial, volatile sulfide inhibiting, oral disease and oral odor preventing and treating care solution. SUMMARY

[0005] In order to overcome the deficiencies of the prior art, one of the purposes of the present application is to provide a preparation for inhibiting bacteria and volatile sulfur compounds, which solves the above-mentioned problems of the conventional technology, has good antibacterial and volatile sulfur compound inhibiting effect, and is mild and non-irritating.

[0006] The second purpose of the present application is to provide an oral care solution using the preparation for inhibiting bacteria and volatile sulfur compounds.

[0007] One of the purposes of the present application is achieved by using the following technical solutions:

[0008] A preparation for inhibiting bacteria and volatile sulfur compounds, comprising a golden camellia tea concentrate and coconut oil, wherein the mass ratio of the golden camellia tea concentrate to the coconut oil is (24-72):(25-75).

[0009] Preferably, the content of golden camellia saponins in the golden camellia tea concentrate is 30wt%-50wt%.

[0010] Camellia nitidissima chi is a plant of Theaceae, Camellia, Camellia subgenus, and is in the same genus and species as Chinese tea, with Camellia nitidissima chi wax-like golden flowers, golden petals, crystal clear, fresh and beautiful, and noble and elegant, and has an unparalleled ornamental value, and is known as the "super star" and "tea queen" in flowers. Camellia nitidissima chi is rich in more than 400 natural trace nutrients, and has a comprehensive and balanced nutritional composition. Camellia nitidissima chi is rich in saponins, tea polyphenols, tea polysaccharides, vitamins, amino acids, and natural organic germanium (Ge), selenium (Se), iron (Fe), copper (Cu), manganese (Mn), zinc (Zn), cobalt (Co), molybdenum (Mo), and vanadium (V), which can comprehensively and organically supplement the trace nutrients required by the human body and play a broad-spectrum health function. Camellia nitidissima chi also contains special color genetic genes DNA, which has important scientific research value. The Camellia nitidissima chi concentrate is a liquid extracted from Camellia nitidissima chi through multiple concentration processes. Specifically, the Camellia nitidissima chi is subjected to the steps of wall breaking, separation, extraction, and concentration by combining the wall breaking technology and the molecular membrane activation directional technology, so as to improve the content of effective components and avoid the damage to active components and the loss of effective components in the heating and concentration process.

[0011] Preferably, the content of the medium-chain fatty acid in the coconut oil is 30wt%-50wt%.

[0012] The coconut oil is prepared by saponification, acidification, water washing, and dehydration of coconuts. The fatty acid contained in the coconut oil has natural comprehensive antibacterial ability and also plays a role as an antioxidant.

[0013] Further preferably, the chain fatty acid is a fatty acid with a carbon atom number of 6-12 on the carbon chain.

[0014] Further preferably, the chain fatty acid is octanoic acid (C8) and decanoic acid (C10), and the mass ratio of octanoic acid to decanoic acid is 1:(0.5-2).

[0015] Preferably, the mass ratio of the Camellia nitidissima chi concentrate to the coconut oil is (30-60):(30-70).

[0016] Further preferably, the mass ratio of the Camellia nitidissima chi concentrate to the coconut oil is (40-50):(30-70).

[0017] Further preferably, the mass ratio of the Camellia nitidissima chi concentrate to the coconut oil is (40-50):(40-60).

[0018] Further preferably, the mass ratio of the Camellia nitidissima chi concentrate to the coconut oil is (40-50):(50-55).

[0019] The second purpose of the application is achieved by the following technical scheme:

[0020] An oral care liquid comprising the above-mentioned preparation for inhibiting bacteria and volatile sulfur compounds.

[0021] Preferably, the preparation in the oral care liquid is 0.049wt%-0.147wt% of the total content, wherein the mass ratio of the camellia sinensis concentrate to coconut oil in the preparation is (24-72):(25-75).

[0022] Compared with the prior art, the present application has the beneficial effects that:

[0023] 1、The preparation for inhibiting bacteria and volatile sulfur compounds of the present application has a strong antibacterial effect through the synergistic effect of the camellia sinensis concentrate and coconut oil, and can effectively inhibit volatile sulfur compounds (VSCs) for preventing and eliminating halitosis. The experiment shows that the synergistic effect is obvious. In addition, the preparation of the present application is more mild than other products on the market, and is free of preservatives, alcohol and compounds. The ingredients of the preparation of the present application are simple, and the preparation materials are food grade and meet the national food safety standards GB2760-2014 of the People's Republic of China.

[0024] 2、The oral care liquid of the present application effectively prevents and treats halitosis (oral odor) by adding the preparation containing the camellia sinensis concentrate and coconut oil, and effectively prevents and treats oral odor by inhibiting the production of volatile sulfur compounds (VSCs) in the oral cavity.

[0025] 3、The oral care liquid of the present application does not cause tooth staining and has the characteristics of being pleasing to the senses, and has obvious inhibitory effect on VSCs, and the antibacterial rate is as high as 99.9%. In addition, the raw material price is low, the audience is wide, and the product has good market potential. In addition, the product has the potential for product conversion due to its quality safety specification. BRIEF DESCRIPTION OF DRAWINGS

[0026] Figure 1 The figure is the trend chart of the reduction of the amount of escherichia coli in the preparation of example 1 of the present application in the process of inhibiting bacteria;

[0027] Figure 2 The figure is the trend chart of the reduction of the amount of staphylococcus aureus in the preparation of example 1 of the present application in the process of inhibiting bacteria;

[0028] Figure 3 The figure is the trend chart of the reduction of the amount of pseudomonas aeruginosa in the preparation of example 1 of the present application in the process of inhibiting bacteria;

[0029] Figure 4 Tendency graph of reduction of C. albicans amount in the process of bacteriostasis for the preparation of Example 1 of the present application;

[0030] Figure 5 Tendency graph of reduction of P. gingivalis amount in the process of bacteriostasis for the preparation of Example 1 of the present application;

[0031] Figure 6 Tendency graph of reduction of E. coli amount in the process of bacteriostasis for the preparation of Example 2 of the present application;

[0032] Figure 7 Tendency graph of reduction of S. aureus amount in the process of bacteriostasis for the preparation of Example 2 of the present application;

[0033] Figure 8 Tendency graph of reduction of P. aeruginosa amount in the process of bacteriostasis for the preparation of Example 2 of the present application;

[0034] Figure 9 Tendency graph of reduction of C. albicans amount in the process of bacteriostasis for the preparation of Example 2 of the present application;

[0035] Figure 10 Tendency graph of reduction of P. gingivalis amount in the process of bacteriostasis for the preparation of Example 2 of the present application;

[0036] Figure 11 Comparison graph of inhibitory effect of the preparation of Example 2 of the present application in hydrogen sulfide solution and methyl mercaptan solution. DETAILED DESCRIPTION

[0037] In order to make the above objectives, features and advantages of the present application more apparent and comprehensible, the specific embodiments of the present application are described in detail below. In the following description, a lot of specific details are set forth in order to fully understand the present application. However, the present application can be implemented in many other ways different from those described herein, and those skilled in the art can make similar improvements without departing from the spirit of the present application, and thus the present application is not limited to the specific embodiments disclosed below. In the following Examples 1-2, the content of camellia saponins in the camellia concentrate is less than 30wt%, and the content of medium-chain fatty acids in the coconut oil is less than 30wt%.

[0038] Example 1

[0039] A preparation for bacteriostasis and inhibition of volatile sulfur compounds includes a camellia concentrate and coconut oil, wherein the content of the camellia concentrate is 0.024wt%, and the content of the coconut oil is 0.025wt%.

[0040] Example 2

[0041] A preparation for inhibiting bacteria and volatile sulfur compounds comprises a Camellia nitidissima compact concentrate and coconut oil, wherein the Camellia nitidissima compact concentrate is 0.072wt%, and the coconut oil is 0.075wt%.

[0042] Example 3

[0043] A preparation for inhibiting bacteria and volatile sulfur compounds comprises a Camellia nitidissima compact concentrate and coconut oil, wherein the Camellia nitidissima compact concentrate is 0.03wt%, and the coconut oil is 0.03wt%. The content of Camellia nitidissima saponins in the Camellia nitidissima compact concentrate is 40wt%, and the content of chain fatty acids in the coconut oil is 30wt%, and the mass ratio of octanoic acid to decanoic acid in the chain fatty acids is 1:0.5.

[0044] Example 4

[0045] A preparation for inhibiting bacteria and volatile sulfur compounds comprises a Camellia nitidissima compact concentrate and coconut oil, wherein the Camellia nitidissima compact concentrate is 0.03wt%, and the coconut oil is 0.07wt%. The content of Camellia nitidissima saponins in the Camellia nitidissima compact concentrate is 30wt%, and the content of chain fatty acids in the coconut oil is 40wt%, and the mass ratio of octanoic acid to decanoic acid in the chain fatty acids is 1:0.5.

[0046] Example 5

[0047] A preparation for inhibiting bacteria and volatile sulfur compounds comprises a Camellia nitidissima compact concentrate and coconut oil, wherein the Camellia nitidissima compact concentrate is 0.04wt%, and the coconut oil is 0.03wt%. The content of Camellia nitidissima saponins in the Camellia nitidissima compact concentrate is 40wt%, and the content of chain fatty acids in the coconut oil is 40wt%, and the mass ratio of octanoic acid to decanoic acid in the chain fatty acids is 1:0.5.

[0048] Example 6

[0049] A preparation for inhibiting bacteria and volatile sulfur compounds comprises a Camellia nitidissima compact concentrate and coconut oil, wherein the Camellia nitidissima compact concentrate is 0.05wt%, and the coconut oil is 0.07wt%. The content of Camellia nitidissima saponins in the Camellia nitidissima compact concentrate is 50wt%, and the content of chain fatty acids in the coconut oil is 40wt%, and the mass ratio of octanoic acid to decanoic acid in the chain fatty acids is 1:0.5.

[0050] Example 7

[0051] A preparation for inhibiting bacteria and volatile sulfur compounds comprises a Camellia nitidissima compact concentrate and coconut oil, wherein the Camellia nitidissima compact concentrate is 0.04wt%, and the coconut oil is 0.06wt%. The content of Camellia nitidissima saponins in the Camellia nitidissima compact concentrate is 50wt%, and the content of chain fatty acids in the coconut oil is 30wt%, and the mass ratio of octanoic acid to decanoic acid in the chain fatty acids is 1:0.5.

[0052] Example 8

[0053] An antibacterial and volatile sulfur compound-inhibiting formulation comprises Camellia chrysantha concentrate and coconut oil, wherein the Camellia chrysantha concentrate contains 0.05 wt% and the coconut oil contains 0.055 wt%. The Camellia chrysantha concentrate contains 30 wt% Camellia chrysantha saponins, and the coconut oil contains 30 wt% chain fatty acids, with the mass ratio of caprylic acid to capric acid in the chain fatty acids being 1:2.

[0054] Comparative Example 1

[0055] One formulation comprises 0.03 wt% of Camellia chrysantha concentrate, wherein the Camellia chrysantha concentrate contains 40 wt% Camellia chrysantha saponins.

[0056] Performance testing

[0057] (1) Antibacterial test

[0058] The inhibitory effects of this combination solution on third-generation Escherichia coli (8099), Staphylococcus aureus (ATCC6538), and Candida albicans (ATCC10231) were tested strictly in accordance with Appendix C3 of GB 15979-2002 "Hygienic Standard for Disposable Sanitary Products". The inhibitory effects of this combination solution on third-generation Pseudomonas aeruginosa (ATCC9027) and Porphyromonas gingivalis (ATCC33277) were tested strictly in accordance with WS / T 650-2019 "Evaluation Methods for Antibacterial and Bacteriostatic Effects".

[0059] like Figures 1-10 The control group used the corresponding standard culture medium. The experimental group used the formulations from Examples 1 and 2.

[0060] All the experiments described above were conducted on the same day under the same conditions. The concentrations chosen were based on preliminary experimental experience with different concentrations of Camellia chrysantha concentrate and coconut oil antibacterial agent.

[0061] from Figures 1-5 Experimental results showed that the formulation of Example 1 exhibited an average bactericidal rate >99.9% against third-generation Escherichia coli (8099), third-generation Staphylococcus aureus (ATCC6538), and third-generation Candida albicans (ATCC10231), indicating strong antibacterial activity. The formulation of Example 1 also showed an average bactericidal rate >99.9% against third-generation Pseudomonas aeruginosa (ATCC9027) and third-generation Porphyromonas gingivalis (ATCC33277), indicating strong antibacterial activity.

[0062] from Figures 6-10Experimental results showed that the formulation in Example 2 exhibited an average bactericidal rate >99.9% against third-generation Escherichia coli (8099), third-generation Staphylococcus aureus (ATCC6538), and third-generation Candida albicans (ATCC10231), indicating strong antibacterial activity. The formulation in Example 2 also showed an average bactericidal rate >99.9% against third-generation Pseudomonas aeruginosa (ATCC9027) and third-generation Porphyromonas gingivalis (ATCC33277), indicating strong antibacterial activity.

[0063] (2) In vitro testing

[0064] In vitro experiments were conducted to test the inhibitory potential of Camellia chrysantha concentrate and coconut oil antibacterial agents on VSCs.

[0065] 1) Add less than 10 μL of the solution described above (oral care solution preparation) to a test tube containing 1 mL of freshly collected human saliva sample and incubate overnight at 37°C. Another test tube containing only saliva serves as a control (i.e., the control group). It is well known that under the latter conditions, a large number of VSCs are formed in the test tube as bacteria break down salivary proteins, forming VSCs from cysteine ​​and methionine. The VSCs in the gas phase above the incubated saliva were determined by gas chromatography, using hydrogen sulfide and methyl mercaptan as standards. The test solution is from Example 2 (i.e., the sample group). All the experiments described above were conducted on the same day under the same conditions.

[0066] from Figure 11 The experimental results showed that the control group contained very high levels of hydrogen sulfide (H2S) and methanethiol (MM), while the sample group contained lower levels of these compounds. This effect was considered to have a significant impact on both H2S and MM. Overall, in the volatile sulfur compound (VSC) removal test, the sample group showed significantly lower levels of both hydrogen sulfide and methanethiol compared to the control group (p<0.01), with a hydrogen sulfide inhibition rate of 52.23% and a methanethiol inhibition rate of 87.65%. This meets the implementation standard of the Laboratory Evaluation Method for Inhibition of Volatile Sulfides (VSCs) T / COCIA19-2022 issued by the China Oral Care Products Industry Association, indicating that the sample has an effect on inhibiting volatile sulfur compounds—hydrogen sulfide and methanethiol.

[0067] (3) Safety testing

[0068] Sample safety testing was conducted. The sample care solution was prepared by mixing 0.072% Camellia chrysantha concentrate, 0.075% coconut oil, and a certain proportion of peppermint oil, sweet orange oil, steviol glycosides, xanthan gum, Tween 20, and deionized water from Example 2 (since the other ingredients are auxiliary components, their proportions are adjusted according to needs and requirements, which will not be elaborated here). Quality and safety testing was conducted strictly in accordance with the "Cosmetic Safety Technical Specifications" (2015 edition). The test results are shown in Table 1, indicating that the care solution sample meets the product specification requirements.

[0069] Table 1

[0070]

[0071] (4) Toxicological experiments

[0072] Toxicological experiments were conducted in animals. A sample care solution was prepared by mixing 0.072% Camellia chrysantha concentrate from Example 2, 0.075% coconut oil, and a certain proportion of peppermint oil, sweet orange oil, steviol glycosides, xanthan gum, Tween 20, and deionized water (since other components are auxiliary ingredients, their proportions are adjusted according to needs and requirements, and will not be elaborated here). The solution was strictly prepared according to the "Disinfection Technical Specifications" (2002 edition) and an acute eye irritation test was performed. The test results are shown in Table 2, indicating that the care solution sample caused no irritation to the eyes of New Zealand rabbits, meeting the requirements of the "Disinfection Technical Specifications" (2002 edition).

[0073] Table 2

[0074]

[0075] (5) Other antibacterial comparative tests

[0076] The formulations of Comparative Example 1 and Example 3 were compared, and the test methods are shown in (1). The test results are shown in the table below.

[0077] Table 3. Test results on bactericidal efficacy against Escherichia coli.

[0078]

[0079]

[0080] Table 4. Test results on bactericidal effect against Staphylococcus aureus.

[0081]

[0082]

[0083] Table 5. Test results on bactericidal efficacy against Candida albicans.

[0084]

[0085] Table 6. Test results on bactericidal efficacy against Pseudomonas aeruginosa.

[0086]

[0087]

[0088] Table 7. Test results on bactericidal efficacy against Porphyromonas gingivalis.

[0089]

[0090] The technical features of the above embodiments can be combined in any way. For the sake of brevity, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0091] The embodiments described above are merely illustrative of several implementations of the present invention, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the invention patent. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these all fall within the protection scope of the present invention. Therefore, the protection scope of this invention patent should be determined by the appended claims.

Claims

1. An oral care fluid characterised in that, The preparation for inhibiting bacteria and inhibiting volatile sulfur compounds; the preparation comprises 0.03 wt % of camellia sinensis concentrate and 0.03 wt % of coconut oil, the content of saponins in the camellia sinensis concentrate is 40 wt %, and the content of medium-chain fatty acids in the coconut oil is 30 wt %, and the mass ratio of caprylic acid to capric acid in the medium-chain fatty acids is 1:0.5.

Images